NAD+ Compounding for Clinics: What You Need to Know About 503A NAD+ Supply
NAD+ subcutaneous injection is one of the fastest-growing add-ons for weight management and longevity clinics. This guide covers 503A compounded NAD+ supply, dosing forms, and how to add it to your GLP-1 program.
NAD+ Compounding for Clinics: What You Need to Know About 503A NAD+ Supply
Nicotinamide adenine dinucleotide (NAD+) has become one of the most popular add-on therapies for weight management and longevity clinics. The subcutaneous injection form — available through 503A compounding pharmacies — is increasingly prescribed alongside GLP-1 therapy as part of comprehensive metabolic programs.
Here is what clinics need to know about sourcing and prescribing 503A compounded NAD+.
What Is 503A Compounded NAD+?
503A compounded NAD+ is a patient-specific preparation of nicotinamide adenine dinucleotide in injectable form, prepared by a licensed 503A compounding pharmacy based on an individual patient prescription.
It is distinct from:
- NAD+ IV infusions: Typically administered in-office over several hours; different regulatory and clinical considerations
- NAD+ supplements: Oral supplements are not compounded medications and have different regulatory status
- NAD+ nasal sprays: A different delivery form with different pharmacokinetics
Available Strengths and Forms
Through MedClinic Partners' partner network, 503A compounded NAD+ subcutaneous injection is available in:
- 500 mg/mL vials: Standard strength for most protocols
- 1,000 mg/mL vials: Higher concentration for patients requiring larger doses
Both are available as multi-dose vials with BUDs up to 12 months when supported by appropriate stability data.
Clinical Use in Weight Management Programs
NAD+ is increasingly prescribed alongside GLP-1 therapy in weight management programs. The rationale includes:
- NAD+ plays a central role in cellular energy metabolism
- GLP-1 therapy can affect mitochondrial function
- Some practitioners believe NAD+ supplementation supports the metabolic benefits of GLP-1 therapy
Important note: The clinical evidence base for NAD+ subcutaneous injection in weight management is still developing. Prescribers should review the current literature and make prescribing decisions based on individual patient needs and documented medical necessity.
Compliance Requirements
503A compounded NAD+ requires the same compliance framework as other compounded medications:
- Valid patient-specific prescription
- Licensed prescriber with valid NPI
- Documentation of medical necessity
- COA on every lot from the compounding pharmacy
Adding NAD+ to Your GLP-1 Program
MedClinic Partners provides access to 503A compounded NAD+ through the same portal as your GLP-1 supply. One account, one delivery, one compliance framework.
Apply for portal access — NPI verified in 60 seconds, no portal fees.
Related reading: Product Catalog · 503A vs 503B Explained · GLP-1 Supply for Functional Medicine
Explore Topics
Written by
Samantha J.
Marketing & Content — MedClinic Partners
Samantha covers healthcare marketing, practice growth, and patient engagement for MedClinic Partners. She writes about the business side of running a compounding-dependent practice — from patient recapture strategies to understanding the regulatory landscape for clinic operators.
Editorial standards: All content on medclinicpartners.com is reviewed by licensed medical operators and compounding compliance specialists before publication. Articles are updated when regulatory guidance changes. This content is for licensed healthcare providers only and does not constitute medical advice.
